

# Ankle and Hindfoot Arthrodesis Using ViviGen® Cellular Bone Matrix

Zachary Ritter, DPM, UPMC Susquehanna, Williamsport, PA

CASE STUDY 3

Arthrodesis is used to treat arthritis, deformity, instability, or pain in the ankle and hindfoot. Although this procedure is the most commonly used technique to treat end-stage ankle arthritis, reported success rates vary widely.<sup>1</sup> One bone grafting option for arthrodesis is autograft. Autograft bone can provide the osteoconductive, osteoinductive and osteogenic properties needed for successful bone fusion; however, the retrieval of the autograft can cause pain and site-morbidity to patients.<sup>2</sup> ViviGen provides all three of these properties using viable lineage-committed bone cells. ViviGen contains viable cortico-cancellous bone matrix, cortico-cancellous chips, and demineralized bone and preclinical studies have suggested bone cells might improve fusion over mesenchymal stem cells by providing better bone deposition<sup>3</sup> while remaining in the defect site longer.<sup>4</sup>

The following describes the use of ViviGen to treat a challenging ankle deformity case.

## Patient

- A 59 year old former smoker, male patient with human leukocyte antigen (HLA) B27
- Complained of pain, progressive deformity, instability, degenerative joint disorder, and ambulatory changes in left ankle that had gradually onset over 15 years
- Failed conservative treatments include orthosis, topical NSAIDS, and arthrocentesis

## Procedure

- Ankle primary fusion was undertaken (Figs. 1&2)
- Valgus rotation with marginal spurring of full thickness cartilage loss observed
- 5 cc of ViviGen was used

## Results

- Fusion was achieved by seven weeks
- Preoperative moderate pain decreased to an occasional ache post-operatively
- Patient was full weight bearing at four weeks using a boot and discontinued boot use at seven weeks

## Conclusion

- Patient was “very pleased with the result” and no complications were observed
- Arthrodesis using ViviGen was successful at inducing fusion within seven weeks (Figs. 3&4)

1. Yasui Y, Hannon CP, Seow D, Kennedy JG. Ankle arthrodesis: A systematic approach and review of the literature. *World J Orthop.* 2016;7(11):700-708.
2. Khan WS, Rayan F, Dhinsa BS, Marsh D. An osteoconductive, osteoinductive, and osteogenic tissue-engineered product for trauma and orthopaedic surgery: how far are we? *Stem Cells Int.* 2012;2012:236231.
3. Reichert JC, Quent VM, Noth U, Huttmacher DW. Ovine cortical osteoblasts outperform bone marrow cells in an ectopic bone assay. *J Tissue Eng Regen Med.* 2011;5(10):831-844.
4. Tortelli F, Tasso R, Loiacono F, Cancedda R. The development of tissue-engineered bone of different origin through endochondral and intramembranous ossification following the implantation of mesenchymal stem cells and osteoblasts in a murine model. *Biomaterials.* 2010;31(2):242-249.

# Ankle and Hindfoot Arthrodesis Using ViviGen® Cellular Bone Matrix

CASE STUDY 3



Fig. 1 AP Preoperative



Fig. 2 Lateral Preoperative



Fig. 3 AP Postoperative  
At 8 Weeks Post Op



Fig. 4 Lateral Postoperative  
At 8 Weeks Post Op

Results from case studies are not predictive of results in other cases. Results in other cases may vary.

LifeNet Health helps to save lives, restore health and give hope to thousands of patients each year. We are the world's most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies—a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.

[LifeNetHealth.org](https://www.LifeNetHealth.org)

The LifeNet Health logo is a registered trademark of LifeNet Health. ViviGen is a registered trademark of LifeNet Health. ©2018 LifeNet Health, Virginia Beach, VA. All rights reserved. 68-20-208.00

The DePuy Synthes logo is a registered trademark of DePuy Synthes, Inc. ©DePuy Synthes 2018. All rights reserved. 092701-180530